Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulmonx (Nasdaq: LUNG) reported that on September 1, 2026, it granted equity awards under its 2025 Inducement Plan to four individuals hired in the third fiscal quarter of 2026.

Rhea-AI Summary

Pulmonx (Nasdaq: LUNG) reported that on September 1, 2026, it granted equity awards under its 2025 Inducement Plan to four individuals hired in the third fiscal quarter of 2026. According to Pulmonx, the new employees received an aggregate of 52,300 restricted stock units (RSUs), approved by the Board’s Compensation Committee as inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4).

Each RSU award vests with one-fourth on the first anniversary of the grant date and the remaining three-fourths in equal quarterly installments over the following three years, subject to continued employment. The Inducement Plan, adopted in November 2025, is used exclusively for equity grants to new hires or after a bona fide break in service.

Market Context

A prior inducement-grant announcement was followed by a 1.26% 24-hour reaction, offering a direct hi...

Analysis

A prior inducement-grant announcement was followed by a 1.26% 24-hour reaction, offering a direct historical comparator. The active S-3/A shelf permits up to $200,000,000 of securities and remains a financing risk.

Key Figures

New employees: 4 individuals RSUs granted: 52,300 RSUs Initial vesting: One-fourth of RSUs +3 more

6 metrics

New employees 4 individuals Third fiscal quarter of 2026

RSUs granted 52,300 RSUs Aggregate inducement awards

Initial vesting One-fourth of RSUs On the one-year anniversary of the Grant Date

Remaining vesting period Three years Equal quarterly installments after initial vesting

Listing rule Nasdaq Listing Rule 5635(c)(4) Inducement material to new employment

Inducement Plan adoption November 2025 Adopted by Pulmonx's Board of Directors

Historical Context

5 past events · Latest: Aug 27 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 27	Investor conferences	Neutral	-1.6%	Management announced participation in two upcoming investor conferences.
Jul 29	2Q26 earnings report	Positive	+28.8%	Gross margin improved while net and adjusted EBITDA losses narrowed.
Jul 28	Investor conference	Neutral	+0.0%	Pulmonx scheduled a fireside chat at the Canaccord Growth Conference.
Jul 15	Earnings date announcement	Neutral	+0.7%	Pulmonx scheduled release of second-quarter 2026 financial results.
Jun 01	Inducement equity grants	Neutral	+1.3%	Pulmonx granted 84,300 RSUs to 17 newly hired employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historical reactions were positive after earnings and the prior inducement-grant announcement, while conference-related notices were flat to negative.

Key Terms

restricted stock units, inducement plan, nasdaq listing rule 5635(c)(4), vesting

4 terms

restricted stock units financial

"The employees received in the aggregate 52,300 restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

inducement plan financial

"Pulmonx granted equity awards under its 2025 Inducement Plan"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

vesting financial

"one-fourth of the RSUs will vest on the one-year anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to four individuals hired by Pulmonx in the third fiscal quarter of 2026. The awards were approved by the Compensation Committee of the Company’s Board of Directors and were granted as an inducement material to the new employees entering into employment with Pulmonx, in accordance with Nasdaq Listing Rule 5635(c)(4). Each award is subject to the terms and conditions of the Inducement Plan and the grant agreements covering the awards.

The employees received in the aggregate 52,300 restricted stock units (“RSUs”). In each case, one-fourth of the RSUs will vest on the one-year anniversary of the Grant Date, with the remainder vesting in equal quarterly installments over the subsequent three-year period, subject to such employee’s continuous employment on each vesting date.

The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees or directors of Pulmonx, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Pulmonx, pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan was adopted by the Company’s Board of Directors in November 2025.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.pulmonx.com.

Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

Investor Contact
Brian Johnston or Webb Campbell
Gilmartin Group
investors@pulmonx.com

FAQ

What equity awards did Pulmonx (NASDAQ: LUNG) grant on September 1, 2026?

Pulmonx granted an aggregate of 52,300 restricted stock units (RSUs) to four new employees on September 1, 2026. According to Pulmonx, these awards were issued under its 2025 Inducement Plan as inducement grants approved by the Board’s Compensation Committee.

How do the Pulmonx (LUNG) inducement RSUs granted in Q3 2026 vest?

The inducement RSUs vest over four years, starting one year after grant. According to Pulmonx, one-fourth vests on the first anniversary of the September 1, 2026 grant date, with the remaining RSUs vesting in equal quarterly installments over the next three years, subject to continued employment.

Who received the Pulmonx 2025 Inducement Plan RSUs granted on September 1, 2026 (LUNG)?

Four individuals hired by Pulmonx in the third fiscal quarter of 2026 received the RSUs. According to Pulmonx, these recipients were new employees, and the equity awards were granted as inducement grants under Nasdaq Listing Rule 5635(c)(4) to support their entry into employment.

What is the purpose of the Pulmonx 2025 Inducement Plan for NASDAQ: LUNG?

The 2025 Inducement Plan is used exclusively for equity grants to new hires or rehires after a bona fide break in service. According to Pulmonx, these awards are granted as material inducements to entering employment, consistent with Nasdaq Listing Rule 5635(c)(4).

When was the Pulmonx 2025 Inducement Plan adopted for LUNG stock awards?

Pulmonx’s Board of Directors adopted the 2025 Inducement Plan in November 2025. According to Pulmonx, this plan provides the framework for granting equity awards, such as the 52,300 RSUs issued on September 1, 2026, to eligible new employees as inducement grants.

How does Nasdaq Listing Rule 5635(c)(4) relate to Pulmonx’s September 2026 RSU grants (LUNG)?

The RSU grants were structured as inducement awards in accordance with Nasdaq Listing Rule 5635(c)(4). According to Pulmonx, this rule allows equity awards to be granted to new employees as a material inducement to employment outside of shareholder-approved equity plans.